Capstone Investment Advisors LLC Makes New $1.19 Million Investment in BeiGene, Ltd. (NASDAQ:BGNE)

Capstone Investment Advisors LLC bought a new position in shares of BeiGene, Ltd. (NASDAQ:BGNE) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,311 shares of the company’s stock, valued at approximately $1,192,000.

Several other hedge funds also recently made changes to their positions in BGNE. Baillie Gifford & Co. grew its stake in BeiGene by 0.6% during the third quarter. Baillie Gifford & Co. now owns 3,705,756 shares of the company’s stock worth $831,979,000 after buying an additional 23,807 shares in the last quarter. FMR LLC increased its stake in BeiGene by 0.8% in the third quarter. FMR LLC now owns 1,660,011 shares of the company’s stock valued at $372,689,000 after acquiring an additional 12,855 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in BeiGene during the second quarter valued at approximately $54,412,000. Connor Clark & Lunn Investment Management Ltd. raised its position in BeiGene by 160.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,854 shares of the company’s stock valued at $50,706,000 after purchasing an additional 138,978 shares in the last quarter. Finally, TD Asset Management Inc lifted its stake in BeiGene by 1.4% during the second quarter. TD Asset Management Inc now owns 114,378 shares of the company’s stock worth $16,318,000 after purchasing an additional 1,599 shares during the last quarter. 48.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BGNE has been the subject of a number of research analyst reports. TD Cowen boosted their price target on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. increased their target price on shares of BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, October 22nd. Citigroup raised their price target on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. StockNews.com cut shares of BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, JMP Securities started coverage on shares of BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price on the stock. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $247.07.

BeiGene Stock Up 7.3 %

Shares of NASDAQ BGNE opened at $206.16 on Friday. The firm has a 50 day moving average price of $212.16 and a two-hundred day moving average price of $184.09. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. BeiGene, Ltd. has a 52-week low of $126.97 and a 52-week high of $248.16.

BeiGene (NASDAQ:BGNE) last announced its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. During the same period in the prior year, the business earned $2.01 earnings per share. The firm’s revenue for the quarter was up 28.2% on a year-over-year basis. Analysts forecast that BeiGene, Ltd. will post -5.38 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Titus B. Ball sold 137 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Oyler sold 6,175 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total value of $1,433,958.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,070 shares of company stock worth $4,901,050. 7.43% of the stock is currently owned by insiders.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.